Strides Pharma Science Balans Gezondheid
Financiële gezondheid criteriumcontroles 3/6
Strides Pharma Science heeft een totaal eigen vermogen van ₹22.1B en een totale schuld van ₹22.2B, wat de schuld-eigenvermogensverhouding op 100% brengt. De totale activa en totale passiva bedragen respectievelijk ₹59.9B en ₹37.7B. De EBIT Strides Pharma Science is ₹6.7B waardoor de rentedekking 2.7 is. Het heeft contanten en kortetermijnbeleggingen van ₹2.5B.
Belangrijke informatie
100.0%
Verhouding schuld/eigen vermogen
₹22.15b
Schuld
| Rente dekkingsratio | 2.7x |
| Contant | ₹2.47b |
| Aandelen | ₹22.15b |
| Totaal verplichtingen | ₹37.75b |
| Totaal activa | ₹59.90b |
Recente financiële gezondheidsupdates
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Recent updates
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Nov 01Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Oct 21After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Aug 14Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?
Jan 26The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It
Jan 11
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹30.9B ) STAR } overtreffen de korte termijn passiva ( ₹29.6B ).
Langlopende schulden: De kortetermijnactiva STAR ( ₹30.9B ) overtreffen de langetermijnschulden ( ₹8.1B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 88.9% ) STAR wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van STAR is de afgelopen 5 jaar gestegen van 67.5% naar 100%.
Schuldendekking: De schuld van STAR wordt goed gedekt door de operationele kasstroom ( 36.9% ).
Rentedekking: De rentebetalingen van STAR op haar schulden worden niet goed gedekt door EBIT ( 2.7 x dekking).